Preventing sexual transmission of HIV: Anti-HIV bioregulatory and homeostatic components of commercial sexual lubricants

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 3-4, 2004, Pages 268-274

  Nguyen, D ^a   Lee, H ^a   Poast, J ^a   Cloyd, M W ^a   Baron, Samuel ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Biological regulation; HIV; Lubricants; Microbicides; Protection; Transmission

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ASTROGLIDE; DRUG METABOLITE; DRUG PRESERVATIVE; GLYCEROL; KY LIQUID; LUBRICATING AGENT; METHYL PARABEN; NON PRESCRIPTION DRUG; POLYQUATERNIUM 23; PROPYL PARABEN; PROPYLENE GLYCOL; REPLENS; UNCLASSIFIED DRUG; VAGISIL; VIAMOR; WET STUFF LITE; WET STUFF PLUS; WET STUFF SECRET; TOPICAL ANTIINFECTIVE AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; COMMERCIAL PHENOMENA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COST; DRUG SAFETY; EPITHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LEUKOCYTE; MALE; PRACTICE GUIDELINE; SEXUAL TRANSMISSION; TEMPERATURE MEASUREMENT; VAGINA EPITHELIUM; DISEASE TRANSMISSION; DRUG EFFECT; LUBRICATION; SAFE SEX; SEXUALLY TRANSMITTED DISEASE; TIME;

ANTI-INFECTIVE AGENTS, LOCAL; HIV INFECTIONS; HOMEOSTASIS; HUMANS; LEUKOCYTES; LUBRICATION; MALE; SAFE SEX; SEXUALLY TRANSMITTED DISEASES, VIRAL; TIME FACTORS;

EID: 17844361904     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Essex M. Human immunodeficiency viruses in the developing world. Adv Virus Res 1999; 53: 71-88.
2. Nicoll A, Gill ON. The global impact of HIV infection and disease. Communicable Disease and Public Health 1999; 2: 85-95.
3. Schwartlander B, Stanecki KA, Brown T, et al. Country-specific estimates and models of HIV and AIDS: Methods and limitations. AIDS 1999; 13: 2445-58.
4. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Family Planning Perspectives 1999; 31: 272-9.
5. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504-10.
6. Van Damme L, Laga M. Vaginal microbicides: An update. In: XIIIth World AIDS Conference. Durham, South Africa, 2000.
7. Kreiss J, Ngugi E, Holmes KK, et al. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268: 477-82.
8. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002; 360: 971-7.
9. Milman G, Sharma O. Mechanisms of HIV/SIV mucosal transmission. AIDS Res Hum Retroviruses 1994; 10: 1305-12.
10. Bcmsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3: 42-7.
11. Zacharopoulos VR, Phillips DM. Cell-mediated HTLV-1 infection of a cervix-derived epithelial cell line. Microbial Pathog 1997; 23: 225-33.
12. Phillips DM, Bourinbaiar AS. Mechanism of HIV spread from lymphocytes to epithelia. Virology 1992; 186: 261-73.
13. Tan X, Phillips DM. Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus. Arch Virol 1996; 141: 1177-89.
14. Smith PD, Li L, Meng G. Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. J Infect Dis 1999;179 (Suppl.): S436-40.
15. Kabat D, Kozak SL, Wehrly K, Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994; 68: 2570-7.
16. Baba TW, Trichel AM, An L, et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 1996; 272: 1486-9.
17. Pauza CD, Emau P, Salvato MS, et al. Pathogenesis of SIVmac251 after a traumatic inoculation of the rectal mucosa in rhesus monkeys. J Med Primatol 1993; 22: 154-61.
18. Pauza CD, Malkovsky M, Salvato MS. SIV transmission across the mucosal barrier. AIDS Res Hum Retroviruses 1994; 10 (Suppl.): S7-10.
19. Baron S, Poast J, Cloyd MW. Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med 1999; 159: 303-10.
20. Baron S, Poast J, Richardson CJ, Nguyen D, Cloyd M. Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: A novel mechanism. J Infect Dis 2000; 181: 498-504.
21. Baron S, Poast J, Nguyen D, Cloyd M. Practical prevention of vaginal and rectal transmission of HIV by adapting the oral defense: Use of commercial lubricants. AIDS Res Hum Retroviruses 2001; 17: 997-1002.
22. van de Wijgert J, Coggins C. Microbicides to prevent heterosexual transmission of HIV: Ten years down the road. Volume 2, No. 1 ed. Vol. 2002: AIDScience (http://aidscience.org/Articles/aidscience015.asp), 2002.
23. Williams LM, Cloyd MW. Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology 1991; 184: 723-8.
24. Tseng CK, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell function. J Exp Med 2002; 195: 43-9.
25. Tseng CK, Miskovsky E, Klimpel GR. Crosslinking CD81 results in activation of TCR gamma delta T cells. Cellular Immunol 2001;207:19-27.
26. McKeating JA, McKnight A, McIntosh K, Clapham PR, Mulder C, Weiss RA. Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. J Gen Virol 1989; 70: 3327-33.
27. Balzarini J, Naesens L, Verbeken E, et al. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998; 12: 1129-38.
28. Reed LJ, Muench H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938; 27: 493-7.
29. Baron S, Cloyd MW. Why is HIV only rarely transmitted normally via the oral cavity? In: HIV-1 Infection, mucosal immunity and pathogenesis. Natcher Conference Center, NIH, Bethesda, MD, 1997.
30. Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastro-duodenal mucosal protection. Physiological Reviews 1993; 73: 823-57.
31. U.S. Department of Health and Human Services, Food and Drug Administration. Vaginal drug products for over-the-counter human use; establishment of a monograph; advance notice of proposed rulemaking. Federal Register 1983; 48: 46694-7291.
32. Weaver MA, Roddy RE. Compliance subgroup analyses in microbicide trials are not risk free. In: Microbicides 2002. Antwerp, Belgium, 2002.
33. van Baare J, Cameron PU, Vardaxis N, et al. The 1998 Lindberg Award. Comparison of glycerol preservation with cryopreservation methods on HIV-1 inactivation. J Burn Care Rehabil 1998; 19: 494-500.
34. Vink C, Yeheskiely E, van der Marel GA, van Boom JH, Plasterk RH. Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein. Nucleic Acids Res 1991; 19: 6691-8.
35. Cameron PU, Pagnon JC, van Baare J, Reece JC, Vardaxis NJ, Crowe SM. Efficacy and kinetics of glycerol inactivation of HIV-1 in split skin grafts. J Med Virol 2000; 60: 182-8.